Zensun USA

Zensun is a clinical-stage biopharmaceutical company focused on developing first-in-class therapeutics for cardiovascular, oncology, and metabolic diseases. The company's lead candidate, Neucardin (recombinant human neuregulin-1), is a novel treatment for chronic heart failure that works by directly repairing damaged cardiomyocytes and improving cardiac function. Zensun utilizes its proprietary neuregulin-based platform to develop a pipeline of biologics and small molecules. Headquartered in Shanghai with a significant R&D presence in San Diego via Zensun USA, the company aims to address significant unmet medical needs globally. Its research is centered on the ErbB signaling pathway and its role in cell growth and repair.